Pharmacology

Action Mechanism of Action Reference
INHIBITOR DNA inhibitor FDA
Primary Target
CD33

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Leukemia, Myeloid, Acute 3 D015470 ClinicalTrials
Myelodysplastic Syndromes 3 D009190 ClinicalTrials
Leukemia 3 D007938 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 D054198 ClinicalTrials
Leukemia, Promyelocytic, Acute 2 D015473 ClinicalTrials
Leukemia, Myelomonocytic, Juvenile 1 D054429 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 1 D015451 ClinicalTrials

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
16.0
Investigations
11.78
Blood and lymphatic system disorders
11.21
Vascular disorders
10.54
Infections and infestations
7.95
Gastrointestinal disorders
5.94
Hepatobiliary disorders
5.36
Respiratory, thoracic and mediastinal disorders
4.6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
4.21
Injury, poisoning and procedural complications
3.83
Nervous system disorders
3.54
Skin and subcutaneous tissue disorders
2.87
Cardiac disorders
2.68
Metabolism and nutrition disorders
2.49
Musculoskeletal and connective tissue disorders
2.3

Cross References

Resources Reference
CAS NUMBER 220578-59-6
ChEMBL CHEMBL1201506
FDA SRS 8GZG754X6M
Guide to Pharmacology 6775